Trial Profile

A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol-PM Plus Carboplatin® Compared to Genexol Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Carboplatin
Indications Ovarian cancer
Focus Registrational; Therapeutic Use
Sponsors Samyang Biopharmaceuticals Corporation

Most Recent Events

03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
24 Sep 2013 9151129 and 9153852 indicate that generic Taxol + carboplatin was the comparator group; NCT and 3088517 say Genexol + carboplatin
16 Sep 2013 Data will be presented at the 2013 American Association for Cancer Research (AACR) conference, according to a Sorrento Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com